Anthropic warns of ‘existential risks to humanity’ from AI; AstraZeneca makes $2bn cancer drug tie-up – business live

Rolling coverage of the latest economic and financial newsPharmaceuticals news: AstraZeneca is investing $2bn in biopharmaceutical oncology company Summit Therapeutics, as part of a tie-up to jointly develop and test anti-cancer drugs.Announcing the deal, AstraZeneca says the two companies will collaborate on a ‌series of studies testing their cancer treatments together.“A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumour types with combinations alongside next-generation immunotherapies.Bispecifics targeting PD-1 and VEGF are rapidly advancing in development and have the potential to improve on current immunotherapies, particularly in lung, breast and gastrointestinal cancers. This opportunity to combine ivonescimab…